Has Jonathan Van Ness confirmed using GLP-1 medication?

No. As of May 2026, there is no public interview, social media post, or verified statement in which Van Ness confirms using semaglutide, tirzepatide, liraglutide, or any other GLP-1 receptor agonist. All claims to the contrary are speculation.

Why do people speculate about celebrity GLP-1 use?

GLP-1 drugs produce rapid, visible weight changes. When any public figure's body composition shifts noticeably, audiences now default to asking about these medications given the massive cultural awareness that emerged in 2023 to 2024. This speculation often lacks evidence and should not be treated as fact.

What weight loss can GLP-1 drugs actually produce?

Clinical trials show mean weight reductions of 15 to 22% over 68 to 72 weeks depending on the specific drug and dose. Individual results vary widely: some patients lose <5% while others exceed 25%. Response depends on genetics, adherence, diet, activity level, and baseline metabolic status.

Are GLP-1 medications safe long-term?

The longest published safety data spans approximately 4 years (SELECT trial for semaglutide). No unexpected safety signals emerged over that period, and cardiovascular outcomes improved. However, questions about very-long-term effects (beyond 5 to 10 years) remain open since these drugs are relatively new for weight management indications.

Jonathan Van Ness and GLP-1: The Documented Public Record

Q: Are GLP-1 medications safe long-term?

The longest published safety data spans approximately 4 years (SELECT trial for semaglutide). No unexpected safety signals emerged over that period, and cardiovascular outcomes improved. However, questions about very-long-term effects (beyond 5 to 10 years) remain open since these drugs are relatively new for weight management indications.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Confirmation status: Not publicly confirmed. All GLP-1 associations are speculative.
What JVN has discussed: Body image, weight fluctuations, and self-acceptance in public interviews and their memoir.
Drug class in question: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide).
Clinical relevance: GLP-1 drugs produce 15 to 22% body weight reduction in trials; visible changes can trigger public speculation regardless of actual use.
HealthRX Medical Team position: Without a public disclosure, attributing medication use to any individual is inappropriate. The clinical data stands on its own.

What Jonathan Van Ness Has Actually Said

Jonathan Van Ness, the Emmy-nominated hairstylist and host known for Queer Eye and their podcast Getting Curious, has spoken openly about body image across multiple platforms. In their 2019 memoir Over the Top, they discussed growing up with a complicated relationship to food and weight, framing body acceptance as a long-term process rather than a single event.

In various podcast episodes and interviews through 2022 and 2023, Van Ness has referenced weight fluctuations without attributing them to any specific pharmaceutical intervention. Their public commentary has centered on self-care, movement, and mental health rather than pharmacological weight management.

The critical distinction: discussing weight changes publicly is not the same as confirming medication use. The HealthRX Medical Team finds zero verifiable primary sources (interviews, social media posts, or on-camera statements) in which Van Ness confirms taking a GLP-1 receptor agonist.

The Speculation: Where It Comes From

Online speculation about Van Ness and GLP-1 drugs appears to stem from two observations: visible body composition changes between television seasons and the broader cultural conversation about celebrity use of semaglutide that intensified throughout 2023 and 2024.

This pattern is not unique to Van Ness. As GLP-1 prescriptions surged past 9 million in the United States by mid-2024, public figures who experienced any visible weight change became subjects of similar speculation. The phenomenon says more about public fascination with these drugs than about any individual's medical choices.

Social media threads, tabloid commentary, and Reddit discussions have circulated theories, but none cite a primary source. The HealthRX Medical Team emphasizes that physical appearance changes can result from dozens of variables: stress, training, dietary shifts, illness, hormonal changes, or simply the passage of time.

Clinical Context: How GLP-1 Receptor Agonists Work

GLP-1 receptor agonists mimic the incretin hormone glucagon-like peptide-1, which is released by the gut after eating. These drugs act on receptors in the pancreas, gut, and central nervous system to produce three primary effects:

Appetite suppression via hypothalamic signaling. GLP-1 drugs cross the blood-brain barrier and act on appetite centers, reducing hunger and increasing satiety signals. A 2021 trial published in the New England Journal of Medicine demonstrated that semaglutide 2.4 mg weekly produced a mean 14.9% body weight reduction versus 2.4% with placebo over 68 weeks.
Delayed gastric emptying. By slowing stomach transit, these drugs extend the feeling of fullness after meals. This effect is most pronounced in the early weeks of treatment and partially attenuates over time.
Glucose-dependent insulin secretion. Originally developed for type 2 diabetes, GLP-1 agonists improve glycemic control by stimulating insulin release only when blood glucose is elevated, reducing hypoglycemia risk compared to older diabetes drugs.

The newer dual-agonist tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors, producing weight reductions of up to 22.5% in the SURMOUNT-1 trial. Both drug classes require weekly subcutaneous injection and gradual dose titration over 4 to 16 weeks to manage gastrointestinal side effects.

Side Effect Profile and Tolerability

The most common adverse effects are gastrointestinal: nausea (reported in 40 to 44% of semaglutide patients), vomiting, diarrhea, and constipation. These typically peak during dose escalation and improve with continued use.

More serious but less common concerns include:

Pancreatitis. Post-marketing surveillance and FDA labeling include warnings about acute pancreatitis risk, though large-scale data suggest the absolute incidence remains low.
Gallbladder events. Rapid weight loss from any cause increases gallstone formation; GLP-1 drugs carry a class warning for cholelithiasis.
Thyroid C-cell tumors. Observed in rodent studies at supratherapeutic doses. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Muscle mass loss. Studies indicate 25 to 40% of weight lost on GLP-1 monotherapy may come from lean mass rather than fat, a concern that has driven recommendations for concurrent resistance training and adequate protein intake (JAMA, 2024).

Who Is Clinically Eligible?

Per current FDA indications, GLP-1 receptor agonists for chronic weight management are approved for adults with:

BMI ≥30 kg/m² (obesity), or
BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)

Off-label prescribing for patients below these thresholds occurs but falls outside evidence-based guidelines. The HealthRX Medical Team notes that cosmetic or aesthetic weight loss in individuals at healthy body weight lacks the risk-benefit data that supports use in clinical obesity.

The HealthRX Medical Team Take

Three points deserve clear clinical commentary:

First, speculation is not evidence. Public figures experience body changes for the same complex reasons as anyone else. Attributing pharmaceutical use without disclosure violates the principle that medical decisions are private. The HealthRX Medical Team does not endorse speculation-based conclusions about any individual's medication use.

Second, the clinical evidence for GLP-1 drugs is strong, independent of any celebrity. The STEP trials, SURMOUNT trials, and SELECT cardiovascular outcomes trial (published in NEJM, 2023) demonstrate that these drugs reduce weight, improve cardiometabolic markers, and in semaglutide's case, reduce major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity.

Third, visibility matters. When a public figure with a large platform discusses body changes (even without naming a drug), it drives search behavior and clinical questions. Clinicians report increased patient inquiries about GLP-1 medications following celebrity-adjacent media cycles. This is neither good nor bad. It simply means accurate, accessible clinical information must be available for people making decisions about their own health.

The appropriate response to public curiosity is not to confirm or deny what any celebrity may be taking. It is to provide the clinical evidence so that individuals and their physicians can make informed decisions based on their own health profiles.

Dose Ranges and Administration

For context, current FDA-approved dosing for weight management:

| Drug | Starting Dose | Target Dose | Frequency | |------|--------------|-------------|-----------| | Semaglutide (Wegovy) | 0.25 mg | 2.4 mg | Weekly SC injection | | Tirzepatide (Zepbound) | 2.5 mg | 10 to 15 mg | Weekly SC injection | | Liraglutide (Saxenda) | 0.6 mg | 3.0 mg | Daily SC injection |

Dose escalation follows a stepwise schedule (typically 4 weeks per step) to minimize GI side effects. Patients who cannot tolerate a target dose may remain on a lower maintenance dose with proportionally reduced efficacy.

Frequently asked questions

›

References

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
FDA. Medications containing semaglutide marketed for type 2 diabetes or obesity. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-obesity
Wegovy (semaglutide) prescribing information. FDA/AccessData. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
Nuijten M, et al. Body composition changes during GLP-1 receptor agonist therapy. JAMA. 2024. https://jamanetwork.com/journals/jama/fullarticle/2812936